GlassScriptPhysician profile
Barbara Chamberlain
NPI 1306935630
$2,324.35
in general payments reported to CMS, 2019-2025
23 companies · $152 in 2025
The $152 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $201 · 2021: $468 · 2022: $351 · 2023: $493 · 2024: $364 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $337.52 | 2019-2024 | |
| Cranial Technologies, INC | $258.94 | 2019-2025 | Doc Band |
| Phadia US INC. | $240.19 | 2019-2025 | Immunocap |
| Glaxosmithkline, LLC. | $199.58 | 2019-2025 | Bexsero |
| Tris Pharma INC | $183.57 | 2020-2025 | Dyanavel Xr, Quillichew Er |
| Pfizer INC. | $174.57 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.64 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $122.74 | 2021-2024 | Crysvita |
| Merck Sharp & Dohme LLC | $98.24 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $76.50 | 2024-2025 | |
| Kaleo, INC. | $67.65 | 2019-2024 | Auvi-Q |
| Stryker Corporation | $61.62 | 2023 | Easyfuse |
| Abbvie INC. | $59.32 | 2020-2021 | |
| Verrica Pharmaceuticals INC. | $59.21 | 2023 | Ycanth |
| Seqirus USA INC | $55.42 | 2024 | Flucelvax |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $49.87 | 2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $37.93 | 2019 | |
| Adlon Therapeutics L.P. | $17.64 | 2021 | |
| Biomarin Pharmaceutical INC. | $17.29 | 2022 | |
| Shire North American Group INC | $16.54 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.46 | 2023 | Qelbree |
| Cumberland Pharmaceuticals, INC. | $15.16 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.75 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.